Literature DB >> 18676766

Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy.

Mohan Hingorani1, Christine L White, Shane Zaidi, Andrew Merron, Inge Peerlinck, Martin E Gore, Christopher M Nutting, Hardev S Pandha, Alan A Melcher, Richard G Vile, Georges Vassaux, Kevin J Harrington.   

Abstract

PURPOSE: To assess the effects of external beam radiotherapy (EBRT) on adenoviral-mediated transgene expression in vitro and in vivo and to define an optimal strategy for combining sodium iodide symporter (NIS)-mediated (131)I therapy with EBRT. EXPERIMENTAL
DESIGN: Expression of reporter genes [NIS, green fluorescent protein (GFP), beta-galactosidase (lacZ), and luciferase (Luc)] from replication-deficient adenoviruses was assessed in tumor cell lines under basal conditions and following irradiation. The effects of viral multiplicity of infection (MOI) and EBRT dose on the magnitude and duration of gene expression were determined. In vivo studies were done with Ad-CMV-GFP and Ad-RSV-Luc.
RESULTS: EBRT increased NIS, GFP, and beta-galactosidase expression in colorectal, head and neck, and lung cancer cells. Radiation dose and MOI were important determinants of response to EBRT, with greatest effects at higher EBRT doses and lower MOIs. Radiation exerted both transductional (through increased coxsackie-adenoviral receptor and integrin alpha(v)) and nontransductional effects, irrespective of promoter sequence (CMV, RSV, hTR, or hTERT). Analysis of the schedule of EBRT followed by viral infection revealed maximal transduction at 24 hours. Radiation maintained increasing radioiodide uptake from Ad-hTR-NIS over 6 days, in direct contrast to reducing levels in unirradiated cells. The effects of EBRT in increasing and maintaining adenovirus-mediated transgene expression were also seen in vivo using GFP- and luciferase-expressing adenoviral vectors.
CONCLUSIONS: Radiation increased the magnitude and duration of NIS gene expression from replication-deficient adenoviruses. The transductional effect is maximal at 24 hours, but radioiodide uptake is maintained at an elevated level over 6 days after infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676766     DOI: 10.1158/1078-0432.CCR-07-4049

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

Review 1.  The biology of the sodium iodide symporter and its potential for targeted gene delivery.

Authors:  Mohan Hingorani; Christine Spitzweg; Georges Vassaux; Kate Newbold; Alan Melcher; Hardev Pandha; Richard Vile; Kevin Harrington
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

Review 2.  Intelligent design: combination therapy with oncolytic viruses.

Authors:  Kathryn Ottolino-Perry; Jean-Simon Diallo; Brian D Lichty; John C Bell; J Andrea McCart
Journal:  Mol Ther       Date:  2009-12-22       Impact factor: 11.454

3.  Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair.

Authors:  Mohan Hingorani; Christine L White; Shane Zaidi; Hardev S Pandha; Alan A Melcher; Shreerang A Bhide; Christopher M Nutting; Konstantinos N Syrigos; Richard G Vile; Georges Vassaux; Kevin J Harrington
Journal:  Mol Ther       Date:  2010-06-29       Impact factor: 11.454

4.  Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Authors:  Feorillo Galivo; Rosa Maria Diaz; Uma Thanarajasingam; Dragan Jevremovic; Phonphimon Wongthida; Jill Thompson; Timothy Kottke; Glen N Barber; Alan Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

Review 5.  Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy.

Authors:  Patrick Baril; Pilar Martin-Duque; Georges Vassaux
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

6.  Bioluminescence imaging of therapy response does not correlate with FDG-PET response in a mouse model of Burkitt lymphoma.

Authors:  Marijke De Saint-Hubert; Ellen Devos; Abdelilah Ibrahimi; Zeger Debyser; Luc Mortelmans; Felix M Mottaghy
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-10

7.  Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution.

Authors:  Xiong Li; Youhong Liu; Yong Tang; Phipps Roger; Meei-Huey Jeng; Chinghai Kao
Journal:  J Gene Med       Date:  2010-06       Impact factor: 4.152

8.  SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I.

Authors:  Maria Rajecki; Mirkka Sarparanta; Tanja Hakkarainen; Mikko Tenhunen; Iulia Diaconu; Venla Kuhmonen; Kalevi Kairemo; Anna Kanerva; Anu J Airaksinen; Akseli Hemminki
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

9.  Improving 131I Radioiodine Therapy By Hybrid Polymer-Grafted Gold Nanoparticles.

Authors:  Marine Le Goas; Marie Paquet; Aurélie Paquirissamy; Julien Guglielmi; Cathy Compin; Juliette Thariat; Georges Vassaux; Valérie Geertsen; Olivier Humbert; Jean-Philippe Renault; Géraldine Carrot; Thierry Pourcher; Béatrice Cambien
Journal:  Int J Nanomedicine       Date:  2019-09-30

10.  External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase.

Authors:  Tzveta D Pokrovska; Egon J Jacobus; Rathi Puliyadi; Remko Prevo; Sally Frost; Arthur Dyer; Richard Baugh; Gonzalo Rodriguez-Berriguete; Kerry Fisher; Giovanna Granata; Katharine Herbert; William K Taverner; Brian R Champion; Geoff S Higgins; Len W Seymour; Janet Lei-Rossmann
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.